Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05036681 | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03420963 |
| Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors |
| terminated |
| Phase 1 |
| 12 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Mar 20, 2026 |
| clinicaltrials |
| NCT04904302 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04338269 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment(CONTACT-03) | terminated | Phase 3 | 522 | Hoffmann-La RocheINDUSTRY | 15 | Mar 19, 2026 | clinicaltrials |
| NCT03922776 | Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer(TILsOV) | terminated | N/A | 36 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04016142 | Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer(ACCRAPAN) | terminated | Phase 2 | 21 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02478112 | Use of a Biodegradable Balloon for the Treatment of Prostate Cancer by Intensity Modulated Radiotherapy (BioPro-RCMI)(BioPro-RCMI) | terminated | N/A | 24 | Centre Oscar LambretOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners(NeuroPrevPTSD) | terminated | Phase 2 | 19 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer(CELLO-1) | terminated | Phase 1 / Phase 2 | 102 | Epizyme, Inc.INDUSTRY | 3 | Mar 10, 2026 | clinicaltrials |
| NCT04651127 | Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer | terminated | Phase 1 / Phase 2 | 5 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02946996 | Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy | terminated | Phase 2 | 41 | Medical University of South CarolinaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06114940 | Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)(PLUTO) | terminated | Phase 2 | 17 | Jinling Hospital, ChinaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | terminated | Phase 1 | 29 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT04895748 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | terminated | Phase 1 | 40 | Novartis PharmaceuticalsINDUSTRY | 7 | Mar 3, 2026 | clinicaltrials |
| NCT05676463 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | terminated | Phase 2 | 6 | Thomas Jefferson UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05192837 | Preoperative Smoking Cessation in Patients Undergoing Surgery(PORTICO) | terminated | N/A | 251 | Luzerner KantonsspitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT00999960 | Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator(PERLE) | terminated | N/A | 29 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06047509 | Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for Guidance | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | terminated | Phase 1 | 17 | Accent TherapeuticsINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors | terminated | Phase 1 | 52 | Regeneron PharmaceuticalsINDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04876651 | The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only | terminated | Phase 3 | 16 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 30 | Novartis PharmaceuticalsINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT06026332 | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting(ABLE-41) | terminated | — | 202 | Ferring PharmaceuticalsINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06716853 | A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma(TEM-GU) | terminated | Phase 1 / Phase 2 | 10 | Genenta ScienceINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 40 | Sonnet BioTherapeuticsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT02886546 | Utility of Dynamic Variables Measured by Calibrated Pulse Contour Analysis of Oesophageal Doppler Monitor for Predicting Fluid Responsiveness During Robot-Assisted Laparoscopic Prostatectomy | terminated | N/A | 26 | Hallym University Kangnam Sacred Heart HospitalOTHER | 0 | Jan 30, 2026 | clinicaltrials |
| NCT05366842 | Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care | terminated | Phase 2 | 3 | Johns Hopkins UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04856189 | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Mamta ParikhOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06457997 | A Study of PHN-010 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 26 | Pheon TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05357027 | HPV16 E6 TCR T Cells for Cervical Carcinoma | terminated | Phase 1 / Phase 2 | 5 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05082025 | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05481645 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. | terminated | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy | terminated | Phase 2 | 19 | Lipomedix Pharmaceuticals Inc.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | terminated | Phase 2 | 54 | ExelixisINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT02948426 | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2026 | clinicaltrials |
| NCT01048853 | Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer | terminated | N/A | 137 | M.D. Anderson Cancer CenterOTHER | 8 | Jan 7, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT03189108 | Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors | terminated | — | 22 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04000477 | Comparison of 2 Types of Cervical Specimens in Patients With a Pathological Screening Smear(ENDOCOL) | terminated | N/A | 3 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04831138 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma | terminated | N/A | 6 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05454358 | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | terminated | Phase 2 / Phase 3 | 12 | Fudan UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06347809 | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine | terminated | — | 24 | Mayo ClinicOTHER | 1 | Dec 15, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 27, 2026source: clinicaltrials